The FDA held a “survival bar” for ivonescimab in an ongoing regulatory review, according to a BioCentury Regulation report. Longer follow-up answered part of the activity question in Western patients, but the primary analysis did not meet the bar in EGFR-mutant non-small cell lung cancer, leaving the next path dependent on additional evidence. Separately, the agency is seeking input on challenges sponsors face with patient-level real-world data (RWD), citing gaps in sharing external patient data and ownership and cross-border privacy constraints that can complicate global evidence generation. Together, the two items point to tightening evidentiary expectations in oncology while simultaneously confronting practical barriers to broader RWD deployment—topics that will shape how sponsors design endpoints, data strategies, and registrational packages.